Child et al 1 recently published the results of a randomized trial comparing standard chemotherapy to high-dose therapy with autologous stem cell rescue in the management of multiple myeloma. They concluded that high-dose therapy with stem cell salvage prolongs progression free as well as overall survival. This is one of the few randomized studies that is attempting to define the role of stem cell transplantation in the management of multiple myeloma. There are some issues, however, that make the data hard to interpret. First, different initial chemotherapy induction regimens were used, with the transplant arm receiving the more intensive treatment. This could have influenced the quality of the responses in high-dose therapy arm. Indeed, it appears that the survival curves first begin to separate at about 8-10 months from the enrollment date and then remain parallel, suggesting an effect of the induction regimen. To clarify this issue, it would have been helpful to describe the type of response patients experienced prior to transplant as compared to the standard arm of therapy. A second issue relates to the larger number of patients in the transplant arm who were able to received interferon therapy (42 vs 78%). This difference could have influenced the PFS in favor of the transplant arm.
TO THE EDITOR
Child et al 1 recently published the results of a randomized trial comparing standard chemotherapy to high-dose therapy with autologous stem cell rescue in the management of multiple myeloma. They concluded that high-dose therapy with stem cell salvage prolongs progression free as well as overall survival. This is one of the few randomized studies that is attempting to define the role of stem cell transplantation in the management of multiple myeloma. There are some issues, however, that make the data hard to interpret. First, different initial chemotherapy induction regimens were used, with the transplant arm receiving the more intensive treatment. This could have influenced the quality of the responses in high-dose therapy arm. Indeed, it appears that the survival curves first begin to separate at about 8-10 months from the enrollment date and then remain parallel, suggesting an effect of the induction regimen. To clarify this issue, it would have been helpful to describe the type of response patients experienced prior to transplant as compared to the standard arm of therapy. A second issue relates to the larger number of patients in the transplant arm who were able to received interferon therapy (42 vs 78%). This difference could have influenced the PFS in favor of the transplant arm. 2 Lastly, the brief 'meta analysis' did not include other studies with more 'negative' findings and the reasons for their exclusion were not provided. The role of autologous bone marrow transplantation in the management of multiple myeloma continues to be controversial, particularly since it is not a curative therapy, and further studies are necessary to further define the patient population most likely to benefit.
No further comments have been received from Dr Child. 
